Inflammatory Myofibroblastic Tumor
Associated Genetic Biomarkers
NCI Definition: A multinodular intermediate fibroblastic neoplasm that arises from soft tissue or viscera, in children and young adults. It is characterized by the presence of spindle-shaped fibroblasts and myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes, and plasma cells. 
Inflammatory myofibroblastic tumors most frequently harbor alterations in ALK, ROS1, NOTCH2, TP53, and TET2 .
NOTCH2 Mutation, TP53 c.217-c.1178 Missense, TP53 c.142-c.212 Missense, TP53 c.1-c.137 Missense, and TP53 Mutation are the most common alterations in inflammatory myofibroblastic tumor .
ALK is the most frequent predictive biomarker for inflammatory myofibroblastic tumor therapies.
Of the biomarker-directed therapies for inflammatory myofibroblastic tumor, 0 are FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting .
Significant Genes in Inflammatory Myofibroblastic Tumor
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.